Enovix

Phase A — Understand the business

Company Overview

Enovix Corporation (Fremont, CA; Nasdaq: ENVX; incorporated Delaware; CIK 0001828318) designs and manufactures lithium-ion battery cells built on a proprietary 3D cellular architecture with a 100% active-silicon anode and no graphite. The founders — drawn from "over 25 years in the hard disk drive and semiconductor industries" — solved silicon's swelling/cracking problem not with new chemistry but with physics: instead of winding electrodes into a conventional jelly-roll, Enovix precisely stacks anode, cathode and separator and applies mechanical constraint that "accommodates silicon's swelling and applies pressure that alleviates the cracking problem". The payoff is energy density: the flagship AI-1 platform delivers a 7,350 mAh smartphone cell at >900 Wh/L — pitched explicitly at AI-enabled smartphones and smart eyewear that need more on-device energy.

How it makes money today vs. tomorrow — the central tension. There are effectively two Enovixes:

1. The legacy/acquired business that pays the bills now — conventional Li-ion and silicon-doped-graphite cells, largely for defense, run through Routejade (acquired Oct 2023; two factories in Nonsan City, South Korea; four automated lines + two electrode-coating lines). This is where essentially all of the ~$32M FY2025 revenue comes from.
2. The silicon-anode story the $1.6B valuation is built on — the AI-1/3D-cell consumer business out of Fab2 in Penang, Malaysia, which has not yet shipped a flagship consumer program at volume.

Target end markets: smartphone, smart eyewear (smart glasses / AR), IoT (wearables, health/wellness, AR/VR, power banks, trackers), and defense.

Customers & concentration (critical): revenue is "derived largely from a limited number of key customers, particularly those in the defense sector. One customer, a defense subcontractor in South Korea, accounted for the majority of our total revenue for fiscal year 2025". In the notes: for FY2025, Customers D and E accounted for ~64% and ~13% of total revenue (≈77% combined). Q1 2026 revenue was again "driven largely by batteries supplied to Korean military contractors".

Contract structure: product-revenue sales (not take-or-pay or recurring SaaS-like). Consumer programs require multi-year customer qualification cycles ("can take years to complete") with safety/qualification testing before any volume orders. Deferred revenue is small ($4.3M current at Apr-5-2026).

Suppliers: Enovix "relies on a manufacturing agreement with a Malaysia-based company for some of the facilities, procurement, and personnel needs" of Fab2 — i.e. a third-party contract-manufacturing dependency sits under the supposedly-owned flagship fab.

Supply Chain

No supply-chain.md exists in the commercial layer (energy wiki is empty) — mapped from the 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. + web.

Upstream → Enovix → end customer:

• Raw materials / cell inputs: silicon (active-anode material), cathode active materials (NMC-class), separators, electrolyte, copper/aluminium current collectors, packaging. The 10-K flags reliance on "manufacturing operations and the components necessary to build our lithium-ion battery cells" with named single-source / concentration risk. Battery materials supply is China-heavy industry-wide.
• Electrode coating / pack assembly: vertically integrated via Routejade (South Korea) — the acquisition's stated rationale was to "vertically integrate electrode coating and battery pack manufacturing". This is a genuine chokepoint Enovix now owns rather than buys.
• Cell manufacturing (the new story): Fab2, Penang Science Park, Malaysia — three lines: R&D pilot, Agility line (began shipping cells Oct 2024), and the High-Volume Manufacturing (HVM) line (Site Acceptance Testing completed; HVM SAT confirmed Jan 6, 2026 ). Fab1 (Fremont) is now new-product development only.
• Contract-manufacturing layer: the Malaysia-based partner providing facilities/procurement/personnel for Fab2 — a single-source operational dependency.
• Downstream / end customers: the named-but-coded South Korean defense subcontractor(s) (Customers D/E, ≈77% of FY25 rev) today; prospectively Honor + a second smartphone OEM (qualification in progress) and a lead smart-eyewear customer (AI-1 commercial production started); plus a drone/defense pipeline management is working to convert to revenue.

Chokepoints / single-source dependencies:

• Customer-side concentration is the dominant chokepoint — one Korean defense buyer is the majority of revenue.
• Fab2 contract-manufacturer dependency — operational single point of failure under the flagship fab.
• Laser/"laser dicing" process step — publicly cited as the cause of 2026 volume-production delays, i.e. an internal process chokepoint, not just a supplier one.

Competitive Advantages (moats)

The real edge — architecture + IP. Enovix's moat is a process/architecture moat: the constrained-stack 3D cell that makes a 100% active-silicon anode survivable. "A majority of our patents relate to battery architecture, secondary batteries, and related structures and materials," supplemented by trade-secret protection on non-patentable know-how. Independent testing has validated the AI-1 as a class-leading energy-density smartphone cell (>900 Wh/L). If the architecture transfers to volume at yield, that is a durable, hard-to-copy advantage in a spec-driven market where OEMs reward the highest mAh in a fixed volume.

Where the moat is weak:

• No volume proof. A moat you can't manufacture at yield isn't yet a moat. The entire bear case is that the lab/pilot advantage hasn't survived the jump to Fab2 HVM (yield, laser dicing).
• Bargaining power is inverted today. With ~77% of revenue from one-to-two defense buyers and zero shipping flagship-smartphone programs, the customer holds all the leverage — qualification cycles "take years," OEMs dictate the test framework (Enovix had to align Honor on a new silicon-specific 0.2C discharge protocol, replacing the legacy 0.7C test). That is the supplier bending to the buyer, not pricing power.
• Credible competitors are advancing commercially faster. Amprius (silicon nanowire, up to 450 Wh/kg) tripled revenue to ~$73M in 2025, hit positive adjusted EBITDA in Q4, and guides $125–135M for 2026 — 4× Enovix's revenue with a shipping product. Different architecture, same "silicon-anode energy density" buyer pitch.

Net: a potentially excellent technical moat that is unproven at the only thing that matters (volume manufacturing) and currently coupled to near-zero customer bargaining power.

Segments

our figures is empty — Enovix does not report disaggregated product/geography segments in a granular table; it operates as a single reportable segment ("Our CEO has been identified as our CODM, who reviews operating results … for the Company as a whole"). So the meaningful "segmentation" is by customer/end-market concentration and geography, not GAAP segments.

• By product line (de facto): essentially all revenue today = conventional Li-ion / silicon-doped-graphite defense cells (Routejade, Korea). The 3D-silicon AI-1 consumer line is pre-volume-revenue.
• By customer (FY2025):
• Customer D ≈ 64% of revenue
• Customer E ≈ 13% of revenue
• "One customer … South Korea defense subcontractor … the majority of total revenue"
• FY2024 had three >10% customers → FY2025 narrowed to two, i.e. concentration increased YoY.
• Receivables concentration (Dec-28-2025): Customers D, E, G ≈ 43% / 12% / 23% of total AR.
• By geography: revenue is "derived … outside the U.S. [for] a significant portion" — predominantly South Korea (defense). Manufacturing is Malaysia (Fab2) + South Korea (Routejade) + India (some activity) + U.S. (HQ/R&D).

Trend & cause: revenue is growing off a tiny base (FY2025 $31.8M, +38% YoY; Q1-26 $7.6M, +49% YoY) but the growth is defense-led and lumpy, not the consumer inflection the stock needs. Q4-25 was a record $11.3M; Q1-26 stepped down to $7.6M; Q2-26 guided $8–9M. That sawtooth is the tell that this is project/order-driven defense revenue, not a ramping consumer franchise.

---

Phase B — Measure performance

Earnings Result (latest print — Q1 2026, quarter ended April 5, 2026)

All figures `` unless noted; $ in thousands.

• Beat: revenue $7.6M cleared the $6.5–7.5M guide and was up 49% YoY. Non-GAAP gross margin 26.3%, the sixth consecutive quarter of positive gross profit (GAAP and non-GAAP). Non-GAAP loss from operations $28.8M beat the $29–32M guide; non-GAAP EPS $(0.14).
• What drove it: Korean military-contractor batteries (the concentrated defense business), not consumer silicon.
• Margin move: GAAP GM nearly 4× the prior-year quarter (20.4% vs 5.1%) — real operating-leverage progress on the defense product, off a tiny base.
• Why net loss widened despite a smaller operating loss inflection: interest expense jumped to $7.0M (+308%) as the full $575M convertible stack carries — financing cost is now a material drag, partially offset by $5.8M interest income on the cash/investments pile.
• Balance-sheet flags (Apr-5-2026):
• Cash $88,751k + short-term investments $439,985k = $528.7M liquidity.
• Inventory $16,451k, up from $13,617k at year-end — building Korea inventory ahead of shipments, a thing to watch (inventory growing faster than revenue can be a demand-timing risk).
• AR $3,943k (down) — clean.
• Long-term debt $520,160k (the converts).
• Accumulated deficit crossed $1.0B: $(1,016,087)k.
• Stockholders' equity ≈ $242.7M (assets $833.9M − liabilities $591.2M).
• Cash burn: operating cash used $(33,072)k for the quarter, nearly double the $(16,907)k prior-year quarter; FCF outflow ~$36.3M including the semiannual 2030-note interest payment and the Korea inventory build. Q2 capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. guided $9–13M.
• Market reaction: stock rose on the print ("Q1 2026 beats forecasts, stock rises") — but the gain reversed within ~10 days when, on May 22, 2026, ENVX fell on a smartphone-battery-delay warning. The pattern: the defense numbers beat, the consumer timeline disappoints — and the market only ultimately cares about the latter.

Earnings Calls (sentiment trend)

No transcripts/ on disk — sentiment read from call summaries/press releases ``.

• Tone has shifted from "validation" to "execution." Q1-26 framing (Talluri): "Enovix is entering a new phase where commercial execution must scale alongside our technology leadership" — explicitly moving the narrative "from validation of technology to disciplined execution against commercialization milestones". That is management acknowledging the credibility problem: the tech is no longer the question, shipping is.
• Recurring phrases: "qualification," "silicon-specific framework," "commercial production," "ramp through the second half," "Korea pipeline." The Korea defense pipeline was quantified at >$130M — a deliberate move to give investors a near-term revenue anchor while the smartphone story slips.
• Things they've (had to) stop saying: firm flagship-smartphone launch dates. The roadmap has repeatedly moved; the latest framing is "qualification over halfway at Honor," "targeted system-level deployments," "initial smart-frame production ramp," "convert the drone pipeline" — milestone language rather than dates. The Street read it as the smartphone inflection being "pushed out multiple quarters".
• Bottleneck honesty: a Q1-26 call was literally titled around "Progress, Cash, and Bottlenecks" — management is being relatively candid about manufacturing/laser-dicing constraints and the cash cost of the build.

Net sentiment: management credibility is the swing factor. Talluri's tone is measured and operator-credible, but the company has spent its "trust me on timing" capital — the call cadence now leans on the defense pipeline and "execution discipline" precisely because the consumer promise keeps slipping.

Comps

EV/Sales reality check: Enovix at ~$1.6B equity (and ~$1.1B EVEnterprise valueWhat it would cost to buy the whole company: its market value plus its debt, minus the cash you would get with it. Often very different from market cap. after netting ~$0.53B liquidity against ~$0.52B converts — roughly EV ≈ market capMarket capitalisationThe share price multiplied by the number of shares. What the market says the equity is worth.) on $31.8M trailing revenue is ~50× trailing sales; Amprius at ~$2.30B on ~$73M is ~31× and growing into it with positive EBITDA. On a sales-and-traction basis Enovix screens expensive relative to the one peer that is actually shipping. QuantumScape carries a far larger cap on essentially no revenue — but that's a different (solid-state EVEnterprise valueWhat it would cost to buy the whole company: its market value plus its debt, minus the cash you would get with it. Often very different from market cap.) lottery ticket, not a clean comp. P/E, EV/EBIT, dividend yield, 5-yr avg ROE: n/a — not meaningful (all loss-making, no dividends, deeply negative ROE on accumulated $1B deficit).

Stock-Price Catalysts (what actually moves ENVX)

Mostly ``. ENVX is a high-beta, 31%-shorted, narrative-driven name — it moves on milestones and timelines, not earnings dollars.

Pattern of >5% moves:

• Up: manufacturing-readiness milestones (HVM Site Acceptance Testing completed Jan 6 2026), AI-1 launch (Jul 2025), independent-test validation of AI-1 energy density (Jan 2026), short-squeeze dynamics (31% SI), capital raises that de-risk runway (paradoxically).
• Down: commercialization delays — the dominant negative catalyst. March 2026 production delays from laser dicing + extended smartphone qualification → PT cuts (Craig-Hallum $10, Benchmark $25→$15). May 22 2026 drop on smartphone-battery-delay warning. Dilution/convert announcements. Insider selling (CEO/COO sold equity & warrants).
• Structural: stock down ~9% over the trailing 12 months while the S&P 500 rose ~23% — chronic underperformance as the inflection keeps receding.

What the market reacts to: one variable — credible evidence that a flagship consumer OEM will ship a 100%-silicon-anode Enovix battery at volume. Defense revenue beats barely move it; smartphone-timeline news (good or bad) moves it hard. Plus a powerful short-squeeze overlay (31% SI) that amplifies any genuinely positive surprise.

---

Phase C — Judge people & books

Management

CEO — Dr. Raj Talluri (President & CEO & Director since January 2023; CODM). This is the single strongest non-technology asset in the story. ~30-year career in portable electronics:

• Micron — SVP/GM Mobile Business Unit; that BU "delivered over $7B in worldwide revenue and over $2B in operating profit in FY2022".
• Qualcomm — SVP/GM IoT BU, "drove the division from incubation to over $1B in product revenue"; also led product management for the Snapdragon flagship apps-processor roadmaps (smartphones/tablets/auto).
• Texas Instruments — 16 years, technical staff → business-unit leadership. PhD (UT Austin), 13 patents.
• Why it matters: the entire thesis is landing and shipping a flagship smartphone. Talluri has spent his career inside the smartphone-silicon supply chain selling to exactly these OEMs. If anyone can convert qualification into a design win, his rolodex and credibility are the right ones. He also brought in Steve Bakos as SVP Worldwide Sales (May 2026) to build the commercial muscle.

Chairman — Thurman John (T.J.) Rodgers (founder of Cypress Semiconductor; sponsor of the SPAC, Rodgers Silicon Valley Acquisition Corp, that took Enovix public in 2021). Held ~22.0M shares ≈ ~10% of shares outstanding at Dec-28-2025 — genuine founder-class skin in the game, and a Silicon Valley operator of real stature. But see the related-party flag below.

Capital allocation: the defining moves are financing, not reinvestment returns yet: raised $575M of convertibles ($215M 2028 @ 3.0% + $360M 2030 @ 4.75%) and acquired Routejade (2023) to vertically integrate + buy the defense revenue that now funds the company. Routejade looks like a shrewd deal in hindsight — it gave Enovix a real, gross-margin-positive revenue line and a manufacturing base while the consumer story matures. ROE/ROIC are deeply negative (accumulated deficit >$1B) — meaningless at this stage; judge them on milestones, not returns.

Red flags:

1. Related-party convertible debt. The 2028 "Affiliate Notes" were issued to an entity affiliated with T.J. Rodgers, the Board Chairman, in a concurrent private placement. The Chairman lending to the company he chairs is a textbook related-party item — disclosed and not necessarily abusive (founders backstopping is common), but it warrants scrutiny on terms and independence.
2. Insider selling. CEO/COO have sold substantial equity and warrants even as public messaging stays bullish — a classic confidence-signal mismatch for a pre-revenue-inflection name.
3. SPAC lineage. Rodgers-sponsored SPAC + private-placement warrants (6.0M to Rodgers Capital; 17.5M warrants @ $11.50 strike) — legacy dilutionDilutionIssuing new shares, so each existing share owns a smaller slice of the same company. overhang and the usual SPAC-era promote dynamics.
4. Serial timeline misses (see Lens 12/13) — a management-credibility red flag even if the tech is real.

Archetype: a professional-operator CEO (Talluri) layered over a founder-financier Chairman (Rodgers) — arguably the right combination for this stage (commercialize + fund), but the related-party financing and insider sales temper the alignment story.

Forensic Red Flags

Income-statement / balance-sheet / cash-flow risks, every figure labelled.

• Cash flow vs. earnings: the divergence runs the right way for once — net loss $(38.3)M but operating cash burnCash burnHow much more cash goes out than comes in, per period. The clock on a company with no profits. $(33.1)M for Q1-26, with large non-cash adds: SBC $11.8M + D&A $9.4M. So GAAP loss is not being flattered by cash it doesn't have; the loss is broadly real cash out the door.
• Stock-based compensation is heavy: $69.8M for FY2025 and $11.8M in Q1-26 — i.e. SBC alone is >2× total FY2025 revenue. Non-GAAP metrics (the 26.3% "GM," the $28.8M non-GAAP op loss) strip this out; watch the GAAP-to-non-GAAP bridge — the favorable non-GAAP framing leans on excluding very real shareholder dilution.
• Inventory growing faster than revenue: $16.5M vs $13.6M QoQ (+21%) on ~flat-to-modestly-up revenue. Management says it's a deliberate Korea pre-build for shipments — plausible and benign if the orders land, a write-down risk if they slip. Track this every quarter.
• Convertible-debt overhang: $520M long-term debt; interest expense $7.0M/qtr and climbing; the 2030 note's semiannual coupon is a visible cash event (drove the $36.3M Q1 FCF outflow). Converts are dilution by another name — conversion or refinancing risk into 2028/2030.
• Going concern: none asserted. Financials "prepared assuming we will continue as a going concernGoing concernAn auditor’s formal doubt that the company can fund itself for the next year. It is a warning about survival, not about performance."; management states cash "will be sufficient to meet our funding requirements over the next twelve months from the date this … Form 10-QForm 10-QThe quarterly version of the annual report. Lighter, and not audited. is filed". With ~$529M liquidity against ~$33M/qtr burn, the literal runway is ~4 years on burn alone — but capex for capacity expansion and the 2028 convert maturity compress that, and management explicitly expects to "need to raise additional funds through … equity, equity-related or debt securities" over time. Dilution is a when, not an if.
• Single-customer revenue-recognition exposure: with ~64% of revenue from one defense buyer, any timing/dispute on that account swings the whole P&L — a concentration risk that is also a rev-rec risk.

Regulatory findings (required sub-section):

• SEC Litigation Releases: None. "No LR found for this company" via EDGAR EFTS over 2021-06-20→2026-06-20.
• SEC AAERs: None. "No AAER found for this company" same period.
• Non-SEC enforcement (web): No material FTC/DOJ/FDA/CFPB enforcement, consent decree, or government fine surfaced for Enovix in searches. (Note: Enovix has been the subject of shareholder securities class-action litigation in the past — common for volatile SPAC-era names — but that is private civil litigation, not a regulator enforcement action; no material regulatory penalty found.)
• 10-K Item 3 (Legal Proceedings): the filing carries the standard legal-proceedings framework; nothing rising to a disclosed material adverse regulatory judgment was extracted.
• Conclusion: No material regulatory or accounting-enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K review as of 2026-06-20. The genuine forensic watch-items are governance/quality (related-party converts, heavy SBC, inventory build, dilution path), not fraud or enforcement.

---

Phase D — Project & stress-test

Forward Projection

This is a pre-inflection, loss-making name with no FY revenue guidance — a precise multi-year EPS model would be false precision. I build a directional revenue/EPS path; output ``, inputs labelled. (Per --watchlist rules I do not log a our model Brier forecast in this loop.)

Anchors +: FY2025 rev $31.8M; Q1-26 $7.6M; Q2-26 guide $8–9M; Korea defense pipeline >$130M; FY2025 net loss $(156.6)M / EPS $(0.75); ~218M shares; ~$33M/qtr operating burn; SBC ~$70M/yr.

EPS reality: even the bull case stays loss-making through FY2028E — at this share count and opex ($180M+ FY25 operating expense base ), Enovix needs several hundred million dollars of revenue before GAAP breakeven. The investable question is therefore not near-term EPS; it is "does a flagship smartphone design win convert, and does Fab2 yield hold at volume?" — a binary, ~12–24-month question. Cash runway ($529M) reaches the catalysts; the risk is dilution before then and the inflection slipping a third time.

Bull vs Bear

Bull case. Enovix owns a physically differentiated, IP-protected, independently-validated silicon-anode cell (AI-1, >900 Wh/L) at the exact moment on-device AI is making battery energy density the binding constraint on smartphones and smart glasses. It is run by a smartphone-silicon operator (Talluri) with the rolodex to land OEMs, has de-risked the manufacturing question (HVM SAT done Jan-26), is already gross-margin-positive six quarters running on a real defense business with a >$130M Korea pipeline, has ~$529M of liquidity (multi-year runway), and is 31% shorted — so a single credible flagship design win could trigger both a fundamental re-rate and a violent short squeeze. The smart-eyewear ramp (H2-26) is a nearer, lower-bar consumer beachhead that could prove the platform before the harder smartphone win.

Bear case (permanent-impairment risks).

1. The flagship never ships at volume / ships late and small. Qualification cycles "take years"; the timeline has already slipped repeatedly (laser dicing, May-22 delay warning); OEMs hold all leverage. If on-device-AI demand is met by competitors (Amprius shipping, plus incremental graphite/SiOx improvements from incumbents like ATL/Samsung SDI/LG), Enovix's window closes and the architecture becomes a great paper that never scaled.
2. Manufacturing yield at Fab2 disappoints. SAT ≠ high yield at volume. The bear thesis is precisely that the pilot-to-HVM jump destroys the unit economics; a structural yield problem would impair the whole thesis.
3. Dilution grinds the equity. ~$33M/qtr burn, $575M of converts maturing 2028/2030, explicit intent to raise more equity — even a successful Enovix may dilute holders heavily on the way, and a delayed one almost certainly raises equity at depressed prices.

Pre-mortem (18 months out, thesis broke): It's Dec 2027. The Honor program "completed qualification" but the design win went to a competitor on yield/cost, or shipped in a niche SKU at trivial volume. Fab2 HVM yields stalled below the level needed for OEM cost targets. Enovix did a dilutive equity raise in 2027 at <$5 to bridge to the 2028 converts. Revenue is ~$60M, still defense-led; the stock is a perennial "next year" story and the short thesis won.

Are multiples too high? On traction, yes — ~50× trailing sales vs Amprius ~31× with positive EBITDA and 4× the revenue. ENVX is priced as an option on a flagship smartphone win, not as a business. That's defensible if you underwrite the binary; it's expensive if you don't.

Contrarian view (what the market refuses to see): The crowd is fixated on the smartphone binary and treats defense as boring filler. But the Routejade defense business + >$130M Korea pipeline + smart-eyewear ramp may quietly compound Enovix into a $100–150M-revenue, gross-margin-positive specialty battery maker even if the flagship phone never lands — which would make today's ~$1.6B a different (lower-multiple, but real) valuation rather than a zero. The asymmetric mistake bears may make is assuming "no flagship phone = broken company," when the floor under the equity is harder than the short interestShort interestHow many shares have been borrowed and sold by people betting the price falls. implies. Conversely, the bull mistake is assuming the squeeze is the thesis.

Devil's Advocate (short-seller)

Dismantling the bull case:

• Revenue concentration is a loaded gun. ~64% from one Korean defense subcontractor. Lose or delay that account and the income statement craters — and defense procurement is exactly the kind of lumpy, politically-exposed, single-buyer revenue that can vanish for a year. The "diversified end markets" story is fiction today.
• The moat may be weaker than bulls think. A constrained-stack architecture that can't be manufactured at yield (laser dicing) is a lab trophy, not a moat. Incumbents (ATL, Samsung SDI, LG Energy, CATL) are pushing SiOx/silicon-blend graphite and have infinitely more manufacturing scale; they don't need 100% silicon to ship "good enough" higher-density cells into the same phones — and they're already in the phones.
• Most dangerous competitor bulls underrate: Amprius. Different architecture, same buyer pitch (highest energy density), but already shipping, $73M revenue tripling, positive adjusted EBITDA. While Enovix qualifies, Amprius sells. The "pure-play silicon-anode leader" crown may already be slipping.
• Worst capital-allocation / governance items: related-party 2028 converts to the Chairman's affiliate, heavy SBC ($70M/yr, >2× revenue), CEO/COO insider selling into the bullish narrative. None is fatal alone; together they read as a team monetizing/financing around a story that keeps slipping.
• What must hold for today's ~$7 price: a credible path to a flagship smartphone design win within ~18 months and acceptable Fab2 yield and no value-destroying dilution before then. All three must break right.
• If growth disappoints 20–30%: there's no earnings to compress — the damage is to the narrative and the multiple. A third smartphone-timeline slip likely takes the stock back toward the $5–6 / Benchmark-cut zone and forces a dilutive raise, which compounds the de-rate. Down 40–60% is on the table on a single bad qualification update.
• Single permanent-impairment scenario (most plausible): Fab2 HVM yields structurally miss OEM cost targets → no flagship win → Enovix becomes a sub-scale defense/eyewear battery maker carrying $575M of converts. Plausibility: moderate — this is genuinely the base-rate outcome for "revolutionary battery architecture transfers to mass production," which historically fails far more often than it succeeds.

Management Questions (ordered by information value)

1. Honor / lead smartphone OEM: what specifically remains between "qualification over halfway" and a binding volume purchase order, and what is the realistic month for first commercial shipments — committed, not aspirational?
2. Fab2 HVM yield: what is current yield on the HVM line vs. the yield required to hit your lead OEM's cell-cost target, and what is the gap-closure plan/timeline (incl. the laser-dicing fix)?
3. If the flagship smartphone win does not materialize by end-2027, what does the business look like on defense + smart-eyewear + IoT alone — revenue, gross margin, and cash burn?
4. Customer concentration: what is the path to getting any single customer below ~30% of revenue, and over what timeframe?
5. Dilution: given ~$33M/qtr burn and the 2028 converts, what is your explicit financing plan — do you expect to raise equity before the 2028 maturity, and under what stock-price conditions?
6. Smart eyewear: name the magnitude — what unit volumes and revenue does the lead smart-eyewear customer's H2-26 ramp imply for FY2027, and is it a reference platform or a shipping consumer product?
7. Korea >$130M pipeline: what portion is contracted vs. pipeline, and over how many quarters does it convert to recognized revenue?
8. Non-GAAP bridge: SBC is running >2× revenue — what is the multi-year plan to bring SBC down as a % of revenue, and how should investors think about the real (post-dilution) economics?
9. Related-party converts: can you walk through the independence and terms of the 2028 Affiliate Notes issued to the Chairman's affiliate, and the board process that approved them?
10. Insider selling: how should shareholders reconcile management equity/warrant sales with public confidence in the commercialization timeline?
11. Incumbent threat: why won't ATL/Samsung SDI/LG/CATL silicon-blend cells be "good enough" for AI smartphones, eliminating the need for a 100%-silicon architecture?
12. Amprius: they're shipping with positive EBITDA while you qualify — what do you do that they can't, and where do you actually compete head-to-head for the same socket?
13. Capacity / capex: what is the total capex (and over what years) to take Fab2 to flagship-smartphone volume, and how is it funded?
14. Routejade: is the defense business a long-term strategic core or a bridge — and would you consider it for divestiture/separation once consumer scales?
15. Capital-allocation philosophy: at what milestone do you expect to generate positive operating cash flow, and what gates the decision to keep funding the consumer build vs. harvesting the defense base?

---